Oct
2
The Spirit of Our Age
Filed Under B2B, Big Data, Blog, Industry Analysis, internet, STM, Uncategorized, Workflow | Leave a Comment
This is not the age of Trump and it is not the age of Brexit. No one will remember the narrow minded bigotry associated with the US presidential candidate referred to this week by Bruce Springsteen as “a moron”, or the mass suicide attempt of the British people in their own descent into intolerance and isolationalism, if democracies act with the wisdom with which we credit them. As an optimist I believe that we will remember this period as one typified by Jemma Redmond, who died aged 38 in August but whose obituary reached the Guardian last week.
http://www.theguardian.com/technology/2016/sep/20/jemma-redmond-obituary?CMP=Share_iOSApp_Other
Let me make one thing clear at the start. I did not know Jemma. I came across her company, Ourobotics (www.ourobotics.com) when doing research in advances in 3D printing 18 months ago. I had heard her give a talk (https://www.labtube.tv/video/ourobotics-the-future-of-bioprinting) full of modesty about the advances she had made, full of justified hope for its future impact. I read an interview with her when she was asked what she would like to have printed for herself. Her response – a uterus – was clearly an in joke that I did not understand, though I do now. What I remember was an unaffected personality from the modest Dublin suburb of Tallaght, child of a construction worker and an office worker, who developed a compulsion to solve a problem, gathered the educational qualifications to do it, won a Google Europe funding award, built a start-up inside a Cork-based accelerator in biotechnology and had five patents pending on her accomplishments so far. And then she sadly, suddenly, died.
All of which brings us to the problem she chose to solve. She spoke about the disparity between the huge increase in the number of organs needed for transplant and the modest increase in the number of donors. She identified the issues surrounding the fact that research labs capable of growing human tissue and building the blueprints in software for replicating organs from them were not located close to the hospitals and surgeons capable of using them. So she dedicated herself to the biotechnology of 3D printing using “human ink” – keeping cells alive so that they could be transported and rebuilt into new pieces of human tissue. She believed that growing organs was a less likely solution than transplanting sections of tissue that would result in organic growth. She built a ten jet printer that could store and use human cells, and she demonstrated that her $176,00 prototype could be produced and sold for $12500, within the price range of the world’s 60,000 hospitals.
And she was not just a clever person who got lucky. Listen to her account of lugging her heavy prototype around America to get finance and support. She carefully places the printer on a table in order to demonstrate it, but the table tips as she does so and the machine falls to the floor. So she edges it aside with her foot, while continuing to engage her audience with her presentation. In other words, she walked where all of us have walked who sought, as entrepreneurs, to engage or persuade or cajole support or finance. And she did not do this in Silicon Valley, but in Cork, demonstrating that in Ireland, as in many other parts of the modern world, dreams of the digital future can come alive in a networked society. When the time came, she did not shrink from putting her ideas into a company and leading it as CEO. No doubt our fast moving world will catch up quickly with Jemma’s innovations, though the strong team she leaves at Ourobotics will surely stay very competitive.
Jemma’s ability to drive learning into business development and pitch at goals that stretch the range of human aspiration should be what we mean when we talk about the spirit of our age. I do not know how or why she died so suddenly and that is not the point of this piece. But I do know from the press coverage why the wry comment about printing a uterus got reported. Jemma it appears was born Intersex. In our world, which struggles to increase diversity, reduce gender barriers and allow each of us the full range of opportunity to match our skills and ambitions, this fact, set against her achievements, should alone mark her out of one of the special people who should stand for these troubled but ever hopeful times.
All
Sep
2
The Rise of the Super-Platform?
Filed Under Big Data, Blog, data analytics, eBook, Industry Analysis, Reed Elsevier, Search, semantic web, STM, Uncategorized, Workflow | Leave a Comment
Here on the South Shore of Nova Scotia it is easy to dream dreams and support fantasies, so treat what follows with caution. Also I am entirely without the benefit of talking to anyone at either Wiley or Atypon for several weeks, so my thinking about the purchase of the latter by the former is not supported by any external knowledge or expertise. Yet I have M had a stream of requests wondering whether I know what it means, so walking the shoreline has given me plenty of opportunity to think about it. And whenever I do, I find myself thinking both about the business of consolidation and about the pressing needs of academic and industrial researchers in a data-driven society.
Let’s start with the first and get thoroughly lost en route to the second. Just suppose that the subtle strategists at Wiley have at length decided that buying more journals is no longer a growth strategy. Wiley can grow revenues in education through acquisition, as it has demonstrated. But in the scholarly research market? This is Wiley’s cash cow, and what they want to grow here is margins – or at least drive margins back to where they once were in the glory days of the 1990s when 45% ebitda expectations were the norm. So what if the Wiley choice was recreate InterScience as an updated rival to SpringerLink or ScienceDirect, the rival Springer and Elsevier platforms, or buy Atypon, move their data to that platform and consolidate there at less expense, and with the ability to earn a margin on all the other independent players already on that platform. Just as Wiley bought a whole swathe of institutional publishing rights when it bought Blackwell a generation ago, here it would be buying distribution rights, including a whole tranche of outfits beginning American and ending in Society with a whole lot of words in between that I have difficulty spelling. Add a few more major Atypon players like Sage (coming soon) or McGraw or Emerald or Taylor and Francis and I begin to envisage a conversation that begins “join our super Big Deal off the Atypon platform and we will rival Springer as a power bloc within the librarian’s budget”!
All of this made me recall the early days of ScienceDirect, when Elsevier offered to host the entire marketplace in the interests of scholarship, and were deeply miffed when the rest of the market thought it was more in the interests of Elsevier and politely declined. But surely the age of the Super Hosts is over? Does no one else remember Dialog and what happened to it? Surely the Grand Strategy cannot just be this? While the margins on hosting would be a useful support to net revenues derived from elsewhere in the Wiley STM business, this seems an elaborate way to put another $30 million on the bottom line. So time to think again?
Maybe they bought it for the technology? Atypon is probably best in class, but Wiley have a strong Tech skill set, and already produce very serious Toolsets for researchers. Wiley Spectra Labs would be a prime example. There is nothing Atypon do that Wiley could not do if they devoted the time and investment to it, so this does not seem a fruitful line of enquiry. Another walk – try again!
And on the shoreline of Kingsburg Bay it is easy to reflect on the way in which the data driven society we live in is reflected in the lives of researchers. In the past year I have heard countless stories of research being embedded in the data created by previous research. Repeatability is becoming a key factor, and often one driven by data analytics. I have heard stories of research teams who do not read the literature where it is too voluminous to handle, but search it carefully and semantically for signs of issues that concern them. And I keep on hearing scholars complaining about how hard it is to cross search files located in many different places and governed by different access rules, both at the level of formal data mining and at a less formal level. And does this get better as more evidential data is made available in places like figshare and F1000? Or as the use and value of preprints grows since no one can wait for the published version?
In other words, the big publishers, if they are to stay in the game, must begin to envisage what life will be like in the Age of Data Licensing. When library Big Deal revenues begin to decline, though individual download revenues still grow. The data licensing stream could be a very valuable way to maintain margins, especially since these fees go mostly directly to the bottom line. And here it is worth considering what Elsevier have been about during the quiet dog days of “nothing happens in August”. On 24 August the Mendeley blog invited us all to try out the beta version of Elsevier’s DataSearch, a cross file tool set to allow users to cross search ScienceDirect and certain other files – ArcIV, for example – in conjunction with it . So would it not be a good idea for Wiley to act for the rest of the market, work on a deal which allowed all Atypon-hosted data, owners permitting, to be subject to this sort of licensed searching? And if the user terms were the same for Wiley Atypon as for Elsevier, and, who knows, even Springer Nature, that would surely be in the interests of users and not really a competition issue?
Before fantasy takes flight, let’s recall that there are still a number of smaller hosts around like Ingenta, Highwire and SilverChair. Will they get squeezed out by the availability of sophisticated cross file searching tools on the major repository sites? Atypon in its new guise could be an instrument of consolidation there. And will there be more preprint sites bound into this? Undoubtedly, and Elsevier’s quiet announcement in August of its patent for a machine-based peer review process will help to answer calls for greater speed in article workflow processing just as it annoys the OA lobbyists.
Taken in the context of the past, the Wiley Atypon deal looks odd and untimely. Place it in the context of the data licensing future, and it could be a prescient stroke which retains the cash cow potency of STM at Wiley while the education story unwinds.
« go back — keep looking »